Chiou, Jing-Yuan and Magazzini, Laura and Pammolli, Fabio and Riccaboni, Massimo The Value of Failures in Pharmaceutical R&D. EIC working paper series #1/2012 IMT Institute for Advanced Studies ISSN 2279-6894.
This is the latest version of this item.
- Published Version
Download (455kB) | Preview
We build a cumulative innovation model in which both success and failure provide valuable information for future research. To test this learning mechanism, we use a dataset covering outcomes of world-wide R&D projects in the pharmaceutical industry, and proxy knowledge flows with forward citations received by patents associated with each project. Empirical results confirm theoretical predictions that patents associated with successfully completed projects (i.e., leading to drug launch on the market) receive more citations than those associated to failed (terminated) projects, which in turn are cited more often than patents lacking clinical or preclinical information. We therefore offer evidence of the value of failures as research inputs in (pharmaceutical) innovation.
|Item Type:||Working Paper (EIC working paper series)|
|Additional Information:||The paper was presented at the 4th ZEW Conference on Economics of Innovation and Patenting, Mannheim, May 19-20, 2011. Comments from Andrew Toole, Frank Rothaermel, Ren´e Belderbos, Bart Leten and conference participants are gratefully acknowledged.|
|Uncontrolled Keywords:||JEL-codes: D23; D83; O3|
|Subjects:||H Social Sciences > HB Economic Theory
R Medicine > RS Pharmacy and materia medica
|Research Area:||Economics and Institutional Change|
|Depositing User:||Leonardo Mezzina|
|Date Deposited:||02 Mar 2012 12:06|
|Last Modified:||02 Mar 2012 12:06|
Available Versions of this Item
The Value of Failures in Pharmaceutical R&D. (deposited 22 Feb 2012 15:39)
- The Value of Failures in Pharmaceutical R&D. (deposited 02 Mar 2012 12:06) [Currently Displayed]
Actions (login required)